Reduction of arteriosclerotic nanoplaque formation and size by fluvastatin in a receptor-based biosensor model

Cardiovascular Research

Volumn 58, Issue 3, 2003, Pages 696-705

  Siegel, G ^a   Abletshauser, C ^b   Malmsten, M ^c   Schmidt, A ^d   Winkler, K ^e  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Novartis Pharma GmbH   (Germany)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Atherosclerosis; CSE inhibitor; Ellipsometry; Lipoproteins; Proteoglycan receptor

Indexed keywords

ANION; APOLIPOPROTEIN; BLOOD SUBSTITUTE; CALCIUM ION; FLUINDOSTATIN; GLYCOSAMINOGLYCAN; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEMBRANE PROTEIN; NANOPARTICLE; PROTEOHEPARAN SULFATE; SILICON DIOXIDE;

AMINO ACID SEQUENCE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BINDING AFFINITY; BINDING SITE; BIOSENSOR; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSLIPOPROTEINEMIA; ELECTRIC RESISTANCE; ELLIPSOMETRY; HEART PROTECTION; HUMAN; HYDROPHOBICITY; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID STORAGE; METHYLATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PLAQUE FORMING CELL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; RISK FACTOR; SINGLE DRUG DOSE; SURFACE PROPERTY; TREATMENT OUTCOME;

ADSORPTION; ANTILIPEMIC AGENTS; BIOSENSING TECHNIQUES; CALCIUM; CORONARY DISEASE; FATTY ACIDS, MONOUNSATURATED; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; INDOLES; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MICROSCOPY, POLARIZATION; TIME FACTORS;

EID: 0038206738     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00249-9     Document Type: Article

References (43)

1. Curzen N., Purcell H. Matching the treatment to the patient in hypertension. Practitioner. 241:1997;152-156.
2. Gotto A.M. Jr. Ongoing clinical trials of statins. Am J Cardiol. 88:(4 Suppl):2001;36F-40F.
3. Siegel G, Malmsten M. Molecular model for athero/arteriosclerosis. Patent PCT/EP 97/05212, USPTO 09/319,970, 1997.
4. Siegel G., Malmsten M., Klüßendorf D., Leonhardt W. Physicochemical binding properties of the proteoglycan receptor for serum lipoproteins. Atherosclerosis. 144:1999;59-67.
5. Siegel G., Malmsten M., Klüßendorf D., Michel F. A receptor-based biosensor for lipoprotein docking at the endothelial surface and vascular matrix. Biosensors Bioelectron. 16:2001;895-904.
6. Siegel G., Malmsten M. Plasma lipoproteins, vascular cell-cell and cell-matrix contacts and disease. Pharmacol Toxicol. 83:(Suppl I):1998;113-115.
7. Siegel G., Malmsten M., Klüßendorf D., et al. Physicochemical interaction between plasma lipoproteins and the endothelial cell membrane and vascular matrix proteoglycans. Atherosclerosis. XI:1998;327-331.
8. Malmsten M., Siegel G., Wood W.G. Ellipsometry studies of lipoprotein adsorption. J Colloid Interface Sci. 224:2000;338-346.
9. Schmidt A., Buddecke E. Cell-associated proteoheparan sulfate from bovine arterial smooth muscle cells. Exp Cell Res. 178:1988;242-253.
10. Siegel G., Walter A., Kauschmann A., Malmsten M., Buddecke E. Anionic biopolymers as blood flow sensors. Biosensors Bioelectron. 11:1996;281-294.
11. Ballantyne C.M., McKenney J., Trippe B.S. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol. 86:2000;759-763.
12. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest. 34:1955;1345-1353.
13. Azzam R.M.A., Bashara N.M. Ellipsometry and polarized light. 1989;North-Holland, Amsterdam.
14. 2 surfaces by means of ellipsometry, using different ambient media. J Phys Chem. 97:1993;1656-1660.
15. Malmsten M. Ellipsometry studies of protein layers adsorbed at hydrophobic surfaces. J Colloid Interface Sci. 166:1994;333-342.
16. De Feijter J.A., Benjamins J., Veer F.A. Ellipsometry as a tool to study the adsorption behavior of synthetic and biopolymers at the air-water interface. Biopolymers. 17:1978;1759-1772.
17. Malmsten M., Siegel G., Buddecke E., Schmidt A. Cation-promoted adsorption of proteoheparan sulphate. Coll Surf B: Biointerfaces. 1:1993;43-50.
18. Siegel G., Malmsten M., Klüßendorf D., et al. Blood-flow sensing by anionic biopolymers. J Auton Nerv Syst. 57:1996;207-213.
19. Malmsten M., Claesson P., Siegel G. Forces between proteoheparan sulfate layers adsorbed at hydrophobic surfaces. Langmuir. 10:1994;1274-1280.
20. Siegel G., Malmsten M., Lindman B. Flow sensing at the endothelium-blood interface. Coll Surf A: Physicochem Eng Aspects. 138:1998;345-351.
21. Siegel G., Malmsten M., Klüßendorf D., Walter A., Schmidt A. Chemistry, recognition and function of a natural shear stress biosensor. ACS Polym Mater Sci Eng. 76:1997;573-575.
22. Anber V., Millar J.S., McConnell M., Shepherd J., Packard C.J. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol. 17:1997;2507-2514.
23. Camejo G., Hurt-Camejo E., Wiklund O., Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. Atherosclerosis. 139:1998;205-222.
24. Marquardt D.W. An algorithm for least-squares estimation of nonlinear parameters. J Soc Ind Appl Math. 11:1963;431-441.
25. Trescony P.V., Oegema T.R. Jr., Farnam B.J., Deloria L.B. Analysis of heparan sulfate from the Engelbreth-Holm-Swarm (EHS) tumor. Connect Tissue Res. 19:1989;219-242.
26. Siegel G. Connective tissue: more than just a matrix for cells. Greger R., Windhorst U. Comprehensive human physiology. Vol. 1:1996;173-224 Springer, Berlin.
27. Timpl R. Proteoglycans of basement membranes. Experientia. 49:1993;417-428.
28. Olgemöller B., Schleicher E.D., Schwaabe S., Guretzki H.-J., Gerbitz K.D. High concentrations of low density lipoprotein decrease basement membrane-associated heparan sulfate proteoglycan in cultured endothelial cells. FEBS Lett. 264:1990;37-39.
29. Chait A., Chang M.Y., Olin K., Wight T. Interaction of oxidized LDL with arterial proteoglycans. Atherosclerosis. 134:1997;197.
30. Atkins E.D.T. Molecular architecture of the animal and some microbial extracellular polysaccharides. Walton A.G. Proceedings of the First Cleveland Symposium on Macromolecules. Structure and Properties of Biopolymers:1977;61-85 Elsevier, Amsterdam.
31. Sloop C.H., Dory L., Roheim P.S. Interstitial fluid lipoproteins. J Lipid Res. 28:1987;225-237.
32. Gordon D.J., Rifkind B.M. High-density lipoprotein: The clinical implications of recent studies. N Engl J Med. 321:1989;1311-1316.
33. Siegel G., Malmsten M., Michel F. A primary lesion model for arteriosclerotic microplaque formation. Int J Angiol. 9:2000;129-134.
34. Deslypere J.P. The role of HMG-CoA reductase inhibitors in the treatment of hyperlipidemia: a review of fluvastatin. Curr Ther Res. 56:1995;111-128.
35. Hussein O., Schlezinger S., Rosenblat M., Keidar S., Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 128:1997;11-18.
36. Brown B.G., Zhao X.-Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
37. Corti R., Fayad Z.A., Fuster V., et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions. A longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation. 104:2001;249-252.
38. Georgiou D., Budoff M.J., Kaufer E., et al. Screening patients with chest pain in the emergency department using electron beam tomography: a follow-up study. J Am Coll Cardiol. 38:2001;105-110.
39. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
40. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 94:1996;2013-2020.
41. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
42. Schatz I.J., Masaki K., Yano K., et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet. 358:2001;351-355.
43. Shepherd J. Fibrates and statins in the treatment of hyperlipidemia: an appraisal of their efficacy and safety. Eur Heart J. 16:1995;5-13.